TRG

TRG Ventures is a specialized life science venture studio and holding company based in Denmark that operates under a unique 'biology-first' model. The firm focuses on founding and building biotechnology companies based on deep scientific insights into the extracellular matrix (ECM) and chronic inflammation. TRG Ventures acts as the management entity for a cluster of high-growth biotechs, including Nordic Bioscience, Union Therapeutics, and Key Bioscience. Its portfolio features advanced clinical programs, most notably the PDE4 inhibitor orismilast, which is currently in late-stage clinical development for multiple inflammatory skin conditions.